亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

Anti-infectives targeting Gram-negative 'superbugs'

总结: New-generation polymyxins that target multidrug-resistant Gram-negative bacteria. The lead candidate novel lipopeptide antibiotic is in advanced preclinical development and has demonstrated superior in vivo efficacy and safety over currently used polymyxin antibiotics.

技术优势: - Novel lipopeptide antibiotics targeting multidrug-resistant Gram-negative bacteria
- Greater efficacy (particularly against lung infections) and significantly less nephrotoxicity in animal models than currently available antibiotics
- Identified lead candidate that is amenable to scale-up manufacturing and ready for IND-enabling studies
- Potential for administration via intravenous, inhaled or topical routes

技术应用: - Multidrug resistant MDR gram-negative bacteria
- Infection
- Superbugs'
- Last-line antibiotics

详细技术说明: Using their polymyxin drug discovery platform, researchers from the Monash University have identified a series of proprietary polymyxin analogues that are active against Gram-negative ‘superbugs’.
In vivo efficacy and toxicity studies in rodents demonstrate that, compared with polymyxin B and colistin, the lead candidate lipopeptide can be safely dosed at higher levels to achieve significantly improved efficacy against infections, particularly pneumonia, with significantly less nephrotoxicity.

其他: Monash University has extensive academic and industrial experience in medicinal chemistry, pharmacokinetics/ pharmacodynamics, and in vitro and in vivo evaluations of antibiotics. Monash seeks a partner to complete advanced IND-enabling preclinical assessment of its lead candidate lipopeptide and to undertake clinical development.

欲了解更多信息，请点击这里